Real-world clinical outcome of unresectable locally advanced & de-novo metastatic pancreatic ductal adenocarcinoma: a multicentre retrospective study
Abstract Background Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited treatment options yielding poor outcomes. This study aimed to evaluate the real-world clinical characteristics, treatment patterns, and outcomes of patients with locally advanced unr...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-024-13386-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841559381123006464 |
|---|---|
| author | Mohamed Aseafan Ali H. Alfakeeh Emad Tashkandi Mervat Mahrous Mohammed Alghamdi Bader Alshamsan Marwan Al-Hajeili Safwan Bakhsh Kanan Alshammari Fahad A. Almugbel Abdulhameed H. Alfagih Ahmed Allehebi Mohamed Montaser Mohamed Hamdy Elsafty Khaled Abd Elaziz Elnaghi Ibrahim Issa Eesa Bakshi Sadeem AlSubaie Bandar AlMutairi Hoda Mokhtar Mohamed Aboelatta Nedal Bukhari Ali M. Alzahrani Tusneem Elhassan Ali Alqahtani Shouki Bazarbashi |
| author_facet | Mohamed Aseafan Ali H. Alfakeeh Emad Tashkandi Mervat Mahrous Mohammed Alghamdi Bader Alshamsan Marwan Al-Hajeili Safwan Bakhsh Kanan Alshammari Fahad A. Almugbel Abdulhameed H. Alfagih Ahmed Allehebi Mohamed Montaser Mohamed Hamdy Elsafty Khaled Abd Elaziz Elnaghi Ibrahim Issa Eesa Bakshi Sadeem AlSubaie Bandar AlMutairi Hoda Mokhtar Mohamed Aboelatta Nedal Bukhari Ali M. Alzahrani Tusneem Elhassan Ali Alqahtani Shouki Bazarbashi |
| author_sort | Mohamed Aseafan |
| collection | DOAJ |
| description | Abstract Background Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited treatment options yielding poor outcomes. This study aimed to evaluate the real-world clinical characteristics, treatment patterns, and outcomes of patients with locally advanced unresectable and de-novo metastatic PDAC in Saudi Arabia, providing regional data to compare with international benchmarks. Methods This is a retrospective, multicentre study involving 350 patients diagnosed with unresectable locally advanced or de-novo metastatic PDAC between January 2015 and November 2023. Data were collected from 10 oncology centers across Saudi Arabia. Results The median age at diagnosis was 60 years, with 63% of patients presenting with multiple metastatic sites, primarily in the liver (66.3%). FOLFIRINOX was the most common first-line treatment (55.1%), followed by gemcitabine plus nab-paclitaxel (15.1%). The median PFS for first-line treatment was 5.3 months, with FOLFIRINOX achieving the longest PFS (6.5 months). The median OS was 10.34 months for the entire cohort, with better survival outcomes observed in patients receiving FOLFIRINOX (12.3 months). Independent prognostic factors for PFS and OS included performance status, first-line regimen, and neutrophil-lymphocyte ratio (NLR). Among patients tested, 7.1% had deficient mismatch repair (d-MMR), and 5.8% harbored BRCA mutations. Conclusions This real-world study confirms that clinical outcomes for locally advanced unresectable and metastatic PDAC in Saudi Arabia are consistent with international data, with FOLFIRINOX showing superior outcomes over gemcitabine-based regimens. However, both treatments reflect the persistent poor prognosis of PDAC, underscoring the need for novel therapeutic strategies. Further research is warranted to optimize treatment selection and improve survival outcomes in this population. |
| format | Article |
| id | doaj-art-a1117014df874ad3a61152d581455cf2 |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-a1117014df874ad3a61152d581455cf22025-01-05T12:33:06ZengBMCBMC Cancer1471-24072025-01-012511910.1186/s12885-024-13386-0Real-world clinical outcome of unresectable locally advanced & de-novo metastatic pancreatic ductal adenocarcinoma: a multicentre retrospective studyMohamed Aseafan0Ali H. Alfakeeh1Emad Tashkandi2Mervat Mahrous3Mohammed Alghamdi4Bader Alshamsan5Marwan Al-Hajeili6Safwan Bakhsh7Kanan Alshammari8Fahad A. Almugbel9Abdulhameed H. Alfagih10Ahmed Allehebi11Mohamed Montaser12Mohamed Hamdy Elsafty13Khaled Abd Elaziz Elnaghi14Ibrahim Issa15Eesa Bakshi16Sadeem AlSubaie17Bandar AlMutairi18Hoda Mokhtar19Mohamed Aboelatta20Nedal Bukhari21Ali M. Alzahrani22Tusneem Elhassan23Ali Alqahtani24Shouki Bazarbashi25Section of Medical Oncology, Department of Internal Medicine, Security Forces HospitalComprehensive Cancer Center, Medical Oncology, King Fahad Medical CityCollege of Medicine, Umm Al-Qura UniversityDepartment of Oncology, Prince Sultan Military Medical CityOncology Center, King Saud University Medical CityDepartment of Medicine, College of Medicine, Qassim UniversityDepartment of Medicine, King Abdulaziz UniversityDepartment of Medical Oncology, King Faisal Specialist Hospital and Research Center-JeddahDepartment of Medical Oncology, Ministry of National Guard Health AffairsDepartment of Medical Oncology, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research CentreComprehensive Cancer Center, Medical Oncology, King Fahad Medical CityDepartment of Medical Oncology, King Faisal Specialist Hospital and Research Center-JeddahSection of Medical Oncology, Department of Internal Medicine, Security Forces HospitalMedical Oncology, NCI Cairo UniversityOncology Centre, Faculty of Medicine, Mansoura UniversityCollege of Medicine, Alfaisal UniversityCollege of Medicine, Alfaisal UniversityPathology and Laboratory Medicine, Security Forces HospitalDepartment of Oncology, Prince Sultan Military Medical CityDepartment of Oncology, Prince Sultan Military Medical CityPrince Faisal Cancer Center, King Fahad Specialist Hospital, Qassim Health ClussterDepartment of Oncology, Prince Sultan Military Medical CityComprehensive Cancer Center, Medical Oncology, King Fahad Medical CityResearch Unit, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research CentreDepartment of Medical Oncology, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research CentreDepartment of Medical Oncology, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research CentreAbstract Background Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited treatment options yielding poor outcomes. This study aimed to evaluate the real-world clinical characteristics, treatment patterns, and outcomes of patients with locally advanced unresectable and de-novo metastatic PDAC in Saudi Arabia, providing regional data to compare with international benchmarks. Methods This is a retrospective, multicentre study involving 350 patients diagnosed with unresectable locally advanced or de-novo metastatic PDAC between January 2015 and November 2023. Data were collected from 10 oncology centers across Saudi Arabia. Results The median age at diagnosis was 60 years, with 63% of patients presenting with multiple metastatic sites, primarily in the liver (66.3%). FOLFIRINOX was the most common first-line treatment (55.1%), followed by gemcitabine plus nab-paclitaxel (15.1%). The median PFS for first-line treatment was 5.3 months, with FOLFIRINOX achieving the longest PFS (6.5 months). The median OS was 10.34 months for the entire cohort, with better survival outcomes observed in patients receiving FOLFIRINOX (12.3 months). Independent prognostic factors for PFS and OS included performance status, first-line regimen, and neutrophil-lymphocyte ratio (NLR). Among patients tested, 7.1% had deficient mismatch repair (d-MMR), and 5.8% harbored BRCA mutations. Conclusions This real-world study confirms that clinical outcomes for locally advanced unresectable and metastatic PDAC in Saudi Arabia are consistent with international data, with FOLFIRINOX showing superior outcomes over gemcitabine-based regimens. However, both treatments reflect the persistent poor prognosis of PDAC, underscoring the need for novel therapeutic strategies. Further research is warranted to optimize treatment selection and improve survival outcomes in this population.https://doi.org/10.1186/s12885-024-13386-0Pancreatic cancerDuctal adenocarcinomaLocally advanceDe-novoSurvivalSaudi Arabia |
| spellingShingle | Mohamed Aseafan Ali H. Alfakeeh Emad Tashkandi Mervat Mahrous Mohammed Alghamdi Bader Alshamsan Marwan Al-Hajeili Safwan Bakhsh Kanan Alshammari Fahad A. Almugbel Abdulhameed H. Alfagih Ahmed Allehebi Mohamed Montaser Mohamed Hamdy Elsafty Khaled Abd Elaziz Elnaghi Ibrahim Issa Eesa Bakshi Sadeem AlSubaie Bandar AlMutairi Hoda Mokhtar Mohamed Aboelatta Nedal Bukhari Ali M. Alzahrani Tusneem Elhassan Ali Alqahtani Shouki Bazarbashi Real-world clinical outcome of unresectable locally advanced & de-novo metastatic pancreatic ductal adenocarcinoma: a multicentre retrospective study BMC Cancer Pancreatic cancer Ductal adenocarcinoma Locally advance De-novo Survival Saudi Arabia |
| title | Real-world clinical outcome of unresectable locally advanced & de-novo metastatic pancreatic ductal adenocarcinoma: a multicentre retrospective study |
| title_full | Real-world clinical outcome of unresectable locally advanced & de-novo metastatic pancreatic ductal adenocarcinoma: a multicentre retrospective study |
| title_fullStr | Real-world clinical outcome of unresectable locally advanced & de-novo metastatic pancreatic ductal adenocarcinoma: a multicentre retrospective study |
| title_full_unstemmed | Real-world clinical outcome of unresectable locally advanced & de-novo metastatic pancreatic ductal adenocarcinoma: a multicentre retrospective study |
| title_short | Real-world clinical outcome of unresectable locally advanced & de-novo metastatic pancreatic ductal adenocarcinoma: a multicentre retrospective study |
| title_sort | real world clinical outcome of unresectable locally advanced de novo metastatic pancreatic ductal adenocarcinoma a multicentre retrospective study |
| topic | Pancreatic cancer Ductal adenocarcinoma Locally advance De-novo Survival Saudi Arabia |
| url | https://doi.org/10.1186/s12885-024-13386-0 |
| work_keys_str_mv | AT mohamedaseafan realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT alihalfakeeh realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT emadtashkandi realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT mervatmahrous realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT mohammedalghamdi realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT baderalshamsan realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT marwanalhajeili realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT safwanbakhsh realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT kananalshammari realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT fahadaalmugbel realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT abdulhameedhalfagih realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT ahmedallehebi realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT mohamedmontaser realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT mohamedhamdyelsafty realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT khaledabdelazizelnaghi realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT ibrahimissa realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT eesabakshi realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT sadeemalsubaie realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT bandaralmutairi realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT hodamokhtar realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT mohamedaboelatta realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT nedalbukhari realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT alimalzahrani realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT tusneemelhassan realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT alialqahtani realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy AT shoukibazarbashi realworldclinicaloutcomeofunresectablelocallyadvanceddenovometastaticpancreaticductaladenocarcinomaamulticentreretrospectivestudy |